Swarup Kumar, MD
Hematology & Oncology · Farmington, CTNPI 1629451497
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $8,341 of the $11,546 with a category attached, or 72.2%. 9 manufacturers reported payments, led by Sanofi at 52.4% of the total. 2025 is the largest year on record at $9,427, more than ten times the $44 reported in 2022.
Across 33 payments — averaging $349.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sanofi$6K
- Johnson & Johnson$2K
- Janssen Scientific Affairs, LLC$1K
- Adaptive Biotechnologies Corporation$964
- Janssen Research & Development, LLC$929
- Pfizer$124
- plus $65 from 3 others
Across 26 payments — averaging $32,719 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Janssen Research & Development, LLC$812K
- Bristol Myers Squibb$36K
- E.r. Squibb & Sons, L.L.C.$3K
What the payments were for
- Consulting fees$8,34172%
- Travel & lodging$1,77115%
- Food & beverage$1,39912%
- Education$340%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sanofi | 5 | $6,049 |
| Johnson & Johnson | 5 | $2,020 |
| Janssen Scientific Affairs, LLC | 2 | $1,395 |
| Adaptive Biotechnologies Corporation | 4 | $964 |
| Janssen Research & Development, LLC | 12 | $929 |
| Pfizer | 2 | $124 |
| Amgen | 1 | $27 |
| Gilead | 1 | $21 |
| Jazz Pharmaceuticals Inc. | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$11,546 in reported general payments places this provider in the 75th percentile of 163 hematology & oncology providers in Connecticut.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ValacyclovirValacyclovir Hcl | 14 | $1,730 |
| Dexamethasone | 16 | $206 |
| Pantoprazole Sodium | 20 | $156 |
Paid to pharmacies, not to this prescriber.
Other hematology & oncology in Farmington
- Biree AndemariamFarmington$646K
- Aakash DesaiFarmington$54K
- Oladipo ColeFarmington$44K
- Jeffrey WasserFarmington$22K
- Robert BonaFarmington$7K
- Amer ZeidanNew Haven$807K
- Paul WeinsteinStamford$288K
- Walid ShaibNew Haven$217K
- Madhavi GorusuHartford$207K
- Dinesh KapurNorwich$201K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.